Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
May 5, 2020
No impact from COVID-19 expected on timing of PRIMROSE 1 and 2 and PROLONG trial readouts, enrollment of new patients…
Read morepress release
April 22, 2020
Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolix Small, expected, non-clinically…
Read morepress release
April 14, 2020
Geneva, Switzerland and Boston, MA – Tuesday 14 April, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss…
Read moreMay 28, 2021
June 9, 2020
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840